手术联合辅助放化疗治疗老年口腔颌面部肿瘤的疗效与安全性分析

:-
 
探讨手术联合辅助放化疗治疗老年口腔颌面部肿瘤的疗效与安全性。方法:选取2023年1月至2025年9月收治的110例老年口腔颌面部肿瘤患者,采用随机分组分为联合治疗组与单纯手术组,各55例。单纯手术组行根治性肿瘤切除术;联合治疗组在相同手术后接受辅助放化疗。比较两组1年、2年总生存率(OS)与无进展生存率(PFS)、肿瘤控制情况(局部复发、区域淋巴结及远处转移)及治疗相关不良反应。结果:联合治疗组1年、2年OS及PFS均显著高于单纯手术组(均P<0.05)。联合治疗组局部复发率、区域淋巴结转移率及远处转移率均显著更低(均P<0.05)。在安全性方面,联合治疗组因接受了标准化的预防性止吐与支持治疗,其≥3级恶心(5.45% vs 14.55%)、呕吐(3.64% vs 12.73%)发生率显著低于单纯手术组(P<0.05),其他不良反应发生率组间无统计学差异;长期随访显示,联合治疗组张口受限(9.09% vs 21.82%)及吞咽功能异常(7.27% vs 18.18%)发生率亦显著更低(P<0.05)。结论:在精细化支持治疗与先进放疗技术支持下,手术联合辅助放化疗可提升老年口腔颌面部肿瘤患者生存率与肿瘤控制率,不增加治疗相关毒副反应,还能更好保留长期功能,表明该综合治疗方案兼具疗效与安全性。

脾肾阳虚型糖尿病肾病患者应用紫芪补肾汤联合达格列净治疗的效果及安全性分析

:-
 
目的 探讨紫芪补肾汤联合达格列净治疗脾肾阳虚型糖尿病肾病(DKD)患者的临床疗效,并分析其对糖代谢、肾功能的影响。方法 选取2024年9月~2025年9月于本院就诊的106例DKD患者为研究对象,按照随机数字表法将其分为对照组、研究组,各53例。对照组予以达格列净治疗,研究组予以紫芪补肾汤联合达格列净治疗,连续治疗2个月。统计对比两组临床疗效、不良反应及治疗前后中医证候积分、血糖及糖代谢指标[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、糖原合酶激酶-3β(GSK-3β)、缺氧诱导因子-1α(HIF-1α)]、肾功能相关指标[血尿素氮(BUN)、血肌酐(SCr)、尿微量白蛋白排泄率(UAER)、估算的肾小球滤过率(eGFR)、同型半胱氨酸(Hcy)、胱抑素C(CysC)、碳水化合物反应元件结合蛋白(ChREBP)]、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、肿瘤坏死因子1型受体(TNFR1)、趋化因子配体9(CXCL9)]、血管内皮功能[血管生成抑制蛋白-1(VASH-1)、血管内皮生长因子(VEGF)、内皮素-1(ET-1)、一氧化氮(NO)、血栓素B2(TXB2)]。结果 研究组总有效率为90.57%,明显高于对照组的73.58%(P<0.05);研究组治疗后中医证候积分低于对照组(P<0.05);研究组治疗后FPG、2 h PG、HbA1c、GSK-3β、HIF-1α水平低于对照组(P<0.05);研究组治疗后BUN、SCr、UAER、Hcy、CysC、ChREBP水平低于对照组,eGFR高于对照组(P<0.05);研究组治疗后血清TNF-α、IL-1β、TNFR1、CXCL9水平低于对照组(P<0.05);研究组治疗后VASH-1、NO水平高于对照组,VEGF、ET-1、TXB2水平低于对照组(P<0.05);两组不良反应比较无明显差异(P>0.05)。结论 紫芪补肾汤联合达格列净治疗DKD患者的疗效显著,可降低血糖水平,改善肾功能,抑制炎症反应,减轻血管内皮损伤,且具有一定安全性。

络合统血疗法治疗脾不统血证痔出血的临床疗效与安全性分析:271例门诊病例的回顾性研究

:-
 
目的:评价络合统血疗法治疗脾不统血证痔出血的临床疗效与安全性。方法:采用回顾性病例研究设计,连续纳入广州医科大学附属中医医院肛肠科门诊数据库中2023年1月5日至2025年12月24日痔出血病例。原始记录317条,去重后311例,排除4例,最终纳入307例;其中271例接受络合统血疗法,构成主要疗效与安全性分析集。全部纳入病例中医辨证均为脾不统血证。主要观察指标为治疗前后便血评分、症状总积分、止血时间、疗效分级、不良反应、复发及改行手术情况。计量资料以均数±标准差或M(P25,P75)表示,治疗前后比较采用Wilcoxon符号秩检验。结果:271例络合统血疗法患者中,男性181例(66.79%),女性90例(33.21%);年龄(47.83±16.37)岁。治疗前后便血评分分别为3.96±1.34分和0.72±1.33分,症状总积分分别为9.80±3.27分和2.01±2.37分,差异均有统计学意义(均P < 0.001)。止血时间为3(2,5.5)d。显效201例(74.17%),有效45例(16.61%),无效25例(9.23%),总有效率为90.77%。不良反应18例(6.64%),均为轻中度;复发32例(11.81%);改行手术9例(3.32%)。结论:在脾不统血证痔出血门诊病例中,接受络合统血疗法后,便血评分与症状总积分显著下降,且短期安全性较好。

络合统血疗法治疗脾不统血证痔出血的临床疗效与安全性分析:271例门诊病例的回顾性研究

:-
 
目的:评价络合统血疗法治疗脾不统血证痔出血的临床疗效与安全性。方法:采用回顾性病例研究设计,连续纳入广州医科大学附属中医医院肛肠科门诊数据库中2023年1月5日至2025年12月24日痔出血病例。原始记录317条,去重后311例,排除4例,最终纳入307例;其中271例接受络合统血疗法,构成主要疗效与安全性分析集。全部纳入病例中医辨证均为脾不统血证。主要观察指标为治疗前后便血评分、症状总积分、止血时间、疗效分级、不良反应、复发及改行手术情况。计量资料以均数±标准差或M(P25,P75)表示,治疗前后比较采用Wilcoxon符号秩检验。结果:271例络合统血疗法患者中,男性181例(66.79%),女性90例(33.21%);年龄(47.83±16.37)岁。治疗前后便血评分分别为3.96±1.34分和0.72±1.33分,症状总积分分别为9.80±3.27分和2.01±2.37分,差异均有统计学意义(均P < 0.001)。止血时间为3(2,5.5)d。显效201例(74.17%),有效45例(16.61%),无效25例(9.23%),总有效率为90.77%。不良反应18例(6.64%),均为轻中度;复发32例(11.81%);改行手术9例(3.32%)。结论:在脾不统血证痔出血门诊病例中,接受络合统血疗法后,便血评分与症状总积分显著下降,且短期安全性较好。

络合统血疗法治疗脾不统血证痔出血的临床疗效与安全性分析:271例门诊病例的回顾性研究

:-
 
目的:评价络合统血疗法治疗脾不统血证痔出血的临床疗效与安全性。方法:采用回顾性病例研究设计,连续纳入广州医科大学附属中医医院肛肠科门诊数据库中2023年1月5日至2025年12月24日痔出血病例。原始记录317条,去重后311例,排除4例,最终纳入307例;其中271例接受络合统血疗法,构成主要疗效与安全性分析集。全部纳入病例中医辨证均为脾不统血证。主要观察指标为治疗前后便血评分、症状总积分、止血时间、疗效分级、不良反应、复发及改行手术情况。计量资料以均数±标准差或M(P25,P75)表示,治疗前后比较采用Wilcoxon符号秩检验。结果:271例络合统血疗法患者中,男性181例(66.79%),女性90例(33.21%);年龄(47.83±16.37)岁。治疗前后便血评分分别为3.96±1.34分和0.72±1.33分,症状总积分分别为9.80±3.27分和2.01±2.37分,差异均有统计学意义(均P < 0.001)。止血时间为3(2,5.5)d。显效201例(74.17%),有效45例(16.61%),无效25例(9.23%),总有效率为90.77%。不良反应18例(6.64%),均为轻中度;复发32例(11.81%);改行手术9例(3.32%)。结论:在脾不统血证痔出血门诊病例中,接受络合统血疗法后,便血评分与症状总积分显著下降,且短期安全性较好。
论著

血浆置换治疗抗MDA5阳性皮肌炎伴肺间质纤维化临床疗效及安全性分析

Clinical efficacy and safety analysis of plasmapheresis for anti-MDA 5 positive dermatomositis with lung interstitial fibrosis

:1166-1171
 
目的 探讨血浆置换联合泼尼松(PDN)联合环磷酰胺(CTX)治疗抗黑色素瘤分化相关基因5(MDA5)抗体阳性皮肌炎(DM)伴肺间质纤维化(ILD)患者疗效及安全性。方法 回顾性分析2014年6月—2023年6月普洱市人民医院诊断的MDA5阳性DM伴ILD患者40例,其中治疗组20例,采用血浆置换联合PDN 1 mg/kg每日1次口服,4周后减量,每周减总量10%,CTX 1 g每月1次静脉滴注,共6次治疗;另20例设为对照组,采用PDN 1 mg/kg每日1次口服,4周后减量,每周减总量10%,CTX 1 g每月1次静脉滴注,共6次治疗,分别于治疗后3月、6月检测一氧化碳弥散量(DLCO)、第1秒用力呼气量(FEV1),血清铁蛋白(SF)、C-反应蛋白(CRP)、涎液化糖链抗原(KL-6)、MDA5转阴率行疗效评估。结果 在治疗3个月和6个月时,两组患者的DLCO、FEV1、SF、CRP、KL-6、MDA5转阴率等指标的完全缓解率不一致。其中,3个月时,治疗组上述指标的完全缓解率依次为95%、85%、90%、90%、90%、85%,对照组依次为15%、20%、20%、15%、0%、0%。两组患者在治疗3个月的DLCO、FEV1、SF、CRP、KL-6水平和MDA5转阴数均有所不同。其中治疗组的DLCO、KL-6、CRP水平均较对照组降低(P<0.01),治疗组FEV1水平较对照组升高(P<0.01),治疗组SF水平较对照组降低(P<0.05),两组治疗6个月时,治疗组上述指标缓解率依次为95%、85%、90%、90%、90%、85%,对照组依次为20%、25%、20%、20%、20%、5%。两组患者在DLCO、FEV1、SF、CRP、KL-6水平以及MDA5转阴数和死亡例数方面比较差异均有统计学意义,其中治疗组的DLCO、KL-6和CRP水平均较对照组降低(P<0.01),治疗组FEV1水平较对照组升高(P<0.01),SF水平治疗组较对照组降低(P<0.05)。结论 在MDA5抗体阳性DM伴ILD患者治疗中,给予血浆置换联合PDN、CTX治疗,可以提高疗效,降低病死率。
Objective To explore the effect of plasmapheresis combined with prednisone(PDN)plus cytoxan(CTX)on patients with anti-melanoma differentiation-associated gene 5(MDA 5)antibody-positive dermatomyositis(DM)with interstitial lung disease(ILD). Methods The data of 40 patients with MDA 5 positive DM and ILD diagnosed in the People's Hospital of Pu'er City from June 2014 to June 2023 were retrospectively was analyzed.Twenty patients of the treatment group were treated with plasmapheresis combined with PDN 1mg / kg once daily,which was reduced by 10% per week after 4 weeks.The other 20 patients of the control group were treated with PDN 1mg / kg once daily,which was reduced after 4 weeks by 10% per week,and CTX 1g once per month.diffusing capacity of the lungs for carbon monoxide(DLCO),forced expiratory volume in the first second(FEV1),serum ferritin(SF),C-reactive protein(CRP),Krebs Von den Lungen-6(KL-6)and MDA5 negative conversion rate were measured at 3 and 6 months after treatment,respectively. Results At 3 and 6 months of treatment,complete remission rates of DLCO,FEV1,SF,CRP,KL-6,MDA 5 conversion and other indicators were inconsistent.Among them,at 3 months,the complete response rate of the above indicators in the treatment group was successively:95%,85%,90%,90%,90% and 85%.The control group was 15%,20%,20%,15%,and 0%,0%.Statistical analysis showed that the levels of DLCO,FEV1,SF,CRP,KL-6 and MDA 5 significantly varied at 3 months of treatment.Pairwise comparison of LSD found that the DLCO,KL-6 and CRP levels in the treatment group were significantly lower than the control group(P<0.01),the FEV1 level in the treatment group was significantly higher(P<0.01),and the SF level in the treatment group was significantly lower(P<0.05).After 6 month of treatment,the complete response rate of the above indicators in the treatment group were 95%,85%,90%,90%,90% and 85%,and the complete response rate of the above indicators in the control group was 20%,25%,20%,20%,20% and 5%.Statistical analysis showed the levels of DLCO,FEV1,SF,CRP,KL-6 for the amount of MDA 5 and the number of deaths between two groups were significantly different.Further pairwise comparison of LSD showed that the DLCO,KL-6 and CRP levels in the treatment group were significantly lower compared with the control group(P<0.01),the FEV1 level was significantly increased compared with the control group(P<0.01),and the SF treatment group was significantly decreased compared with the control group(P<0.05). Conclusions In the treatment of patients with MDA 5 antibody positive DM with ILD,the treatment of plasmapheresis combined with PDN and CTX can significantly improve the efficacy and reduce the mortality rate.
论著

成人全麻腹腔镜下疝修补日间手术可行性和安全性分析

Feasibility and safety analysis of laparoscopic inguinal hernia repair ambulatory surgery under general anesthesia in adults

:1357-1362
 
目的 探讨成人全身麻醉(全麻)腹腔镜下腹股沟疝修补日间手术的可行性及安全性。方法 回顾性分析2021年1月—2023年12月广州市第一人民医院收治的进行全麻腹腔镜下疝修补手术治疗的成人患者病历资料,根据患者住院手术模式分为日间手术组、传统手术组。日间手术组采用日间手术模式下全麻腹腔镜腹股沟疝修补术,传统手术组采用传统入院模式下择期全麻腹腔镜下腹股沟疝修补术,对比分析两组可行性(住院时间、住院费用、患者满意度)、安全性(手术时间、手术的出血量、手术并发症的发生率)等。结果 最终纳入199例病例,日间手术组52例(26.1%),传统手术组147例(73.9%)。与传统手术组相比较,日间手术组住院时间、术前住院时间、术后住院时间缩短,满意度评分升高,差异具有统计学意义(P<0.05)。在手术费用、住院总费用、术后24 h疼痛评分、手术时间、手术的出血量、手术并发症的发生率方面,组间比较差异均无统计学意义(P>0.05)。结论 成人全麻腹腔镜下腹股沟疝修补日间手术,能够缩短患者的住院时间,提高患者的住院满意程度,不增加手术风险和并发症发生率,是安全、有效的。
Objective To explore and analyze the feasibility and safety of laparoscopic inguinal hernia repair surgery under general anesthesia in adults.Methods A retrospective analysis was conducted on the medical records of patients admitted to a hospital from January 2021 to December 2023 who underwent laparoscopic hernia repair surgery under general anesthesia.The patients were divided into day surgery group and traditional surgery group based on their hospitalization surgery mode.The daytime surgery group underwent laparoscopic inguinal hernia repair under general anesthesia in the daytime surgery mode,while the traditional surgery group underwent elective laparoscopic inguinal hernia repair under general anesthesia in the traditional admission mode.The feasibility(hospitalization duration,hospitalization cost,patient satisfaction)and safety(surgery duration,surgical bleeding volume,incidence of surgical complications)of the two groups were compared and analyzed.Results A total of 199 cases were enrolled,with 52 cases(26.1%)in the day surgery group and 147 cases(73.9%)in the traditional surgery group.Compared with the traditional surgery group,the daytime surgery group showed a decrease in length of hospital stay,preoperative hospital stay,and postoperative hospital stay,while the satisfaction score increased,and the difference was statistically significant(P<0.05).There was no difference(P>0.05)between the two groups in terms of surgical costs,total hospitalization costs,postoperative 24-hour pain scores,surgical time,surgical bleeding volume,and incidence of surgical complications.Conclusion sLaparoscopic inguinal hernia repair under general anesthesia during the day for adults is safe and effective.
论著

改良直接抽吸取栓术治疗急性脑栓塞的有效性及安全性分析

The efficacy and safety of modified-ADAPT of acute cerebral embolism

:60-65
 
目的 观察改良直接抽吸取栓术(ADAPT)治疗急性前循环大动脉栓塞性脑卒中的有效性与安全性。方法 回顾性分析2022年3月—2023年2月在广州市第一人民医院采用改良ADAPT治疗急性前循环大动脉栓塞性脑卒中的12例患者临床资料。该改良技术核心是血栓抽吸导管或颅内支持导管管头明确越过血栓后才开始直接使用20 mL的注射器进行手动持续抽吸;所有患者术后依据临床症状和影像表现启动规范抗凝药物治疗,每月门诊随访观察有无再发卒中。结果 12例患者闭塞血管均成功再通,其中改良脑梗死溶栓(mTICI )2b~2c级3例(25%),mTICI 3级9例(75%);从穿刺到血管再通平均时间为37.7 min,首次取栓再通8例(66.7%),其中颈内动脉闭塞首次取栓再通成功率达80%,出院时平均美国国立卫生研究院卒中量表(NIHSS)评分(9.00±9.22)分,与术前基础NIHSS评分相比,平均下降7分,术后90 d功能恢复良好(mRS评分0~2分)9例(75%);术后脑出血3例(25%),其中1例为小点状出血(HI1)而无明显症状、1例为血肿<梗死面积的30%并有轻微占位效应的出血(PH1)恢复良好、1例为血肿>梗死面积的30%并有明显占位效应的出血(PH2)术后自动出院,12例患者筛查病因均发现有心房纤颤,9例患者术后依据临床症状和影像表现在早期开展规范抗凝二级预防管理后无再复发。结论 改良ADAPT是治疗急性大动脉栓塞性脑卒中的一种安全可行选择,血管再通效率高,血栓逃逸概率低、临床疗效良好。对心房纤颤患者实施规范抗凝管理可有效预防脑卒中复发。
Objective To observe the efficacy and safety of modified-a direct aspiration first-pass technique(ADAPT)in the treatment of acute anterior circulation aorta embolic stroke.Methods The clinical data of 12 patients with acute anterior circulation arterial embolic stroke treated by modified-ADAPT in our hospital from March 2022 to February 2023 were analyzed retrospectively.The core of the modified technique is that the head of the thrombus aspiration catheter or intracranial support catheter clearly crosses the thrombus before manual continuous suction with a 20 mL syringe.After operation,all patients started standard anticoagulant therapy according to clinical symptoms and imaging manifestations,and monthly outpatient follow-up was conducted to observe whether there was recurrent stroke.Results Occlusive vessels were successfully recanalized in 12 patients,including 3 cases(25%)of mTICI 2b-2c grade and 9 cases(75%)of mTICI 3 grade.The average time from puncture to vascular recanalization was 37.7 min,and the first thrombectomy and recanalization was performed in 8 cases(66.7%).The success rate of internal carotid artery occlusion was 80%.The average NIHSSS score at discharge was(9.00±9.22).Compared with the preoperative NIHSS score,the average score decreased by 7 points.90 days after operation,the function recovered well in 9 cases(75%).Postoperative cerebral hemorrhage occurred in 3 cases(25%),including 1 case of punctate hemorrhage without obvious symptoms,1 case of good recovery of PH1 and 1 case of automatic discharge after PH2.12 patients were found to have atrial fibrillation after screening,9 patients had no recurrence after anticoagulation secondary prevention management according to clinical symptoms and imaging manifestations.Conclusions Modified-ADAPT is a safe and feasible choice for the treatment of acute arterial embolism stroke,with high recanalization efficiency,low thrombus escape probability and good clinical effect.Standardized anticoagulation management can effectively prevent the recurrence of stroke in patients with atrial fibrillation.
论著

避孕药结合宫腔镜手术治疗子宫内膜息肉的临床疗效与安全性分析

Clinical efficacy and safety analysis of contraceptives combined with hysteroscopic surgery in the treatment of endometrial polyps

:105-107
 
目的 探究宫腔镜结合避孕药治疗子宫内膜息肉的临床疗效与对其安全性的分析。方法 随机选取2016年2月—2017年12月内160例子宫内膜息肉患者,分为对照组(80例,宫腔镜治疗)和观察组(80例,宫腔镜结合屈螺酮炔雌醇片治疗),对比两组临床疗效及不良反应的差异性。结果 与对照组相比,观察组患者月经改善效果更佳,其复发率更低,差异有统计学意义(P<0.05);在不良反应的对比中,观察组结果与对照组结果相比较,不存在较大差异(P>0.05)。结论 宫腔镜结合避孕药治疗子宫内膜息肉取得了一定的临床疗效,不良反应并不显著,可推广运用。
Objective To explore the clinical efficacy and safety of hysteroscopy combined with contraceptives in the treatment of endometrial polyps. Methods From February 2016 to December 2017, 160 patients with endometrial polyps were randomly selected and divided into control group (80 cases treated by hysteroscopy) and observation group (80 cases treated by hysteroscopy combined with drospirenone and ethinyl estradiol tablets). The differences of clinical efficacy and adverse reactions between the two groups were compared. Results Compared with the control group, the observation group had better menstruation improvement effect and lower recurrence rate. The difference was statistically significant (P<0.05). In the comparison of adverse reactions, there was no significant difference between the observation group and the control group (P>0.05). Conclusion Hysteroscopy combined with contraceptives has achieved certain clinical efficacy in the treatment of endometrial polyps, and the adverse reactions are not significant, which can be popularized and applied.
论著

妊娠期糖尿病孕妇应用胰岛素治疗对妊娠结局的影响及安全性分析

Effect and safety of insulin therapy on pregnancy outcome in pregnant women with gestational diabetes mellitus

:39-42
 
目的 分析妊娠期糖尿病(gestational diabetes mellitus,GDM)孕妇接受胰岛素治疗对妊娠结局的影响及安全性。方法 将2018年7月—2020年7月接诊且行常规治疗的50例GDM孕妇作为对照组,将同期接诊且在对照组基础上行胰岛素治疗的50例GDM孕妇作为观察组,对组间血糖控制效果、生活质量(SF-36)、治疗效果、不良妊娠结局、不良反应展开分析。结果 (1)组间血糖指标在治疗前无明显差异(P>0.05);治疗后,观察组血糖控制效果优于对照组(P<0.05);(2)观察组SF-36评分高于对照组,且治疗效果(96.00%)优于对照组(82.00%,P<0.05);(3)观察组出现3例不良妊娠结局(6.00%),对照组出现11例不良妊娠结局(22.00%,P<0.05);(4)观察组发生3例不良反应(6.00%),对照组发生2例不良反应(4.00%,P>0.05)。结论 对GDM孕妇实施胰岛素治疗,可以改善孕妇血糖水平,减少不良妊娠结局,提高孕妇生活质量,安全可靠,值得推广。
Objective To analyze the effect and safety of insulin therapy on pregnancy outcome in pregnant women with gestational diabetes mellitus (GDM). Methods A total of 50 pregnant women with GDM who received conventional treatment from July 2018 to July 2020 were induded in the control group, and 50 pregnant women with GDM who received insulin treatment on the basis of the control group were induded in the observation group. Results (1) There was no significant difference in blood glucose index between two groups before treatment(P> 0.05); after treatment, the blood glucose control effect of the observation group was better than that of the control group(P<0.05); (2) SF-36 score of the observation group was higher than that of the control group, and the treatment effect (96.00%) was better than that of the control group (82.00%,P<0.05); (3) there were 3 cases of adverse pregnancy outcomes (6.00%) in the observation group and 11 cases (22.00%) in the control group; (4) there were 3 cases of adverse reactions (6.00%) in the observation group and 2 cases (4.00%) in the control group(P> 0.05). Conclusion Insulin therapy for pregnant women with GDM could improve the blood glucose level of pregnant women, reduced adverse pregnancy outcomes, improved the quality of life of pregnant women, which is safe and reliable, and is worthy of promotion.
出版者信息








《广州医药》公众号